goserelin acetate

P4, N=62, Recruiting, Aristotle University Of Thessaloniki | Not yet recruiting --> Recruiting

P=N/A, N=349, Active, not recruiting, Peking University People's Hospital | Recruiting --> Active, not recruiting | N=240 --> 349

P3, N=27, Active, not recruiting, ECOG-ACRIN Cancer Research Group | Trial primary completion date: May 2028 --> Jun 2025

P=N/A, N=0, Withdrawn, Sir Mortimer B. Davis - Jewish General Hospital | N=65 --> 0 | Not yet recruiting --> Withdrawn

P2, N=130, Completed, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Active, not recruiting --> Completed | Trial completion date: May 2025 --> Dec 2024

P2/3, N=102, Active, not recruiting, Sir Mortimer B. Davis - Jewish General Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2025 --> Apr 2027

P2, N=65, Active, not recruiting, Jules Bordet Institute | Trial completion date: Oct 2024 --> Jan 2025 | Trial primary completion date: Aug 2024 --> Jan 2025

Initially treated for early-stage disease with surgery, chemotherapy, radiotherapy, and ET, she progressed to metastatic disease and received ribociclib, letrozole, and goserelin, achieving a partial response. Managed with prednisolone and azathioprine, ribociclib was reintroduced at a reduced dose and later escalated to full dose. This case report highlights the importance of a multidisciplinary approach to balance oncologic efficacy with hepatologic safety.

P2, N=74, Not yet recruiting, University of Chicago | Initiation date: Jul 2024 --> Jan 2025

P=N/A, N=42, Completed, Medical College of Wisconsin | Active, not recruiting --> Completed

P=N/A, N=14, Recruiting, Fudan University | Not yet recruiting --> Recruiting

There are subgroups of patients, such as those with low baseline cancer burden and PTEN/ERG wild-type status, more likely to achieve good response with nADT. In the case of long term oncological benefit to be proven, nADT might be an additional therapeutic resource for these patients.

Methods Pre/perimenopausal pts with no prior systemic therapy for aggressive HR+/HER2− ABC were randomized 1:1 to RIB + letrozole/anastrozole + goserelin or physician's choice of combo CT. Contrary results in the CT arm suggest that these signatures warrant further studies on their potential predictive value. These data are hypothesis generating and should be interpreted with caution due to small sample sizes.

P2, N=79, Active, not recruiting, Alliance for Clinical Trials in Oncology | Trial primary completion date: Jun 2024 --> Nov 2025

P2, N=190, Recruiting, The First Affiliated Hospital with Nanjing Medical University

With longer follow-up and most patients off ribociclib, NATALEE continues to demonstrate iDFS benefit with ribociclib plus NSAI over NSAI alone in the overall population and across key subgroups. Observed adverse events remained stable.

P2, N=31, Active, not recruiting, Janssen Pharmaceutical K.K. | Trial completion date: Sep 2025 --> Dec 2027

P2, N=376, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed

P2, N=20, Recruiting, Manish Patel | Trial completion date: Sep 2024 --> Oct 2025 | Trial primary completion date: Sep 2024 --> Sep 2025

P4, N=137, Recruiting, Novartis Pharmaceuticals | Trial completion date: Mar 2030 --> Feb 2028 | Trial primary completion date: Feb 2030 --> Jan 2028

P2, N=620, Recruiting, Fudan University | N=140 --> 620

The efficacy of neoadjuvant treatment with letrozole plus palbociclib does not seem to depend on pretreatment RS for patients with RS ≥18. However, around half of patients with HR-positive/HER2-negative early breast cancer with an RS 26-100 at baseline achieved molecular downstaging with this regimen.

Both Ribociclib and palbociclib have similar CBR, PFS and toxicity profile.

The DUCT study addresses an unmet medical need by investigating the repurposing of dutasteride to enhance treatment response and improve clinical outcome for patients with R/M SDC, especially those with limited alternative treatment options, such as HER2-negative cases. By repurposing a registered low-cost drug, this trial's findings could be readily applied into clinical practice.

P2, N=176, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Dec 2028 --> May 2028 | Trial primary completion date: May 2028 --> Feb 2028

P2, N=33, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Jul 2024 --> Mar 2025

P=N/A, N=979, Completed, Janssen Pharmaceutical K.K. | Active, not recruiting --> Completed | Trial completion date: Oct 2025 --> Aug 2024

P=N/A, N=60, Completed, Seattle Institute for Biomedical and Clinical Research | Active, not recruiting --> Completed

P2, N=30, Recruiting, German Oncology Center, Cyprus

P=N/A, N=60, Active, not recruiting, Seattle Institute for Biomedical and Clinical Research | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Sep 2023 --> Sep 2024

P2, N=80, Recruiting, Xijing Hospital

Pre/perimenopausal women also received goserelin. Trial registration: ClinicalTrials.gov number, NCT03423199. Study registration date: February 06, 2018.

P1/2, N=9, Active, not recruiting, Praful Ravi, MB BCHir, MRCP | N=93 --> 9

P3, N=608, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2024 --> Jun 2025

P2, N=716, Recruiting, Fudan University | Phase classification: P1/2 --> P2

P2, N=85, Completed, University Hospital, Akershus | Recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2024 | Trial primary completion date: Dec 2023 --> Jul 2024

P2, N=32, Not yet recruiting, OHSU Knight Cancer Institute

P1/2, N=93, Active, not recruiting, Praful Ravi, MB BCHir, MRCP | Trial primary completion date: Jul 2024 --> Jul 2025

P2; Trial completion date: Jan 2030 --> Jul 2031 | Trial primary completion date: Jul 2025 --> Jan 2026

P4, N=62, Not yet recruiting, Aristotle University Of Thessaloniki

Although tamoxifen therapy is an essential treatment, the long-term benefit for patients with luminal A and B subtype is not well understood. Secondary analysis of 952 ER-positive/HER2-negative patients with luminal A or B molecular subtype from the Stockholm Tamoxifen 2, 3 and 5 trials randomized to receive tamoxifen therapy (tamoxifen alone or with goserelin) or control. Our findings suggest a long-term benefit from tamoxifen for most patients with less aggressive tumor characteristics irrespective of molecular subtype, but the benefit differed by menopausal status. Luminal B patients with PR-positive, lymph node-negative or low genomic risk tumors had a higher risk as compared to patients with luminal A tumors.

P1, N=48, Recruiting, Novartis Pharmaceuticals | Trial primary completion date: Dec 2031 --> Dec 2026